----item----
version: 1
id: {0E746191-53C6-488D-AD7A-44DCD6A5159F}
database: master
path: /sitecore/content/Pharma/MedtechInsight/Home/Articles/AtA typical questions
parent: {D5B965D3-AC3D-4A7F-90E6-65193022C6B5}
name: AtA typical questions
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----field----
field: {A4F985D9-98B3-4B52-AAAF-4344F6E747C6}
name: __Workflow
key: __workflow
content-length: 38

{926E6200-EB76-4AD4-8614-691D002573AC}
----version----
language: en
version: 1
revision: c55392d3-6d45-409e-8b20-3a114c3315a3

----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 2052

<p> <style> <!-- .links { font-family: Arial, Helvetica, sans-serif; font-size: 12px; text-decoration:none; color:#3399ff; } --> </style> <tr> <td> <a>Introduction </a></td> <td><a>How does it work?</a></td> <td>Typical AtA questions</td> <td><a>Biographies </a></td> <td><a>Contact us</a></td> </tr>   <tr> <td><escenic_non_breaking_space></escenic_non_breaking_space></td> </tr> <tr> <td> <ul> <li>Starting from the merger of Pfizer with Wyeth, what are the common therapeutic areas of two companies and particularly which products of Wyeth have close or identical indications to Pfizer&rsquo;s products?</li> </ul> <ul> <li><strong>We are trying to look at what might be expected from Government mandated price cuts in Japan in 2010. Any source information that you may have would be much appreciated.<br> </strong><a>View published response</a><br> </li> </ul> <ul> <li><strong>Can you provide me with information about drug availability and reimbursement of medication in the Philippines? <escenic_non_breaking_space></escenic_non_breaking_space> Are brand and generic medicines available and what % of the population has access to healthcare in that country?<br> </strong><a>View published response</a><br> </li> </ul> <ul> <li>I am looking for an evaluation on the problems and challenges related to the EC Clinical Trials Directive. This means that pharmaceutical companies have to invest strong resources, even if only some molecules arrive to the final step of commercialisation. <escenic_non_breaking_space></escenic_non_breaking_space> I would like to know if there are some referred data on this topic, specifically on the matter of expenditures.</li> </ul> <ul> <li>Could you devote a report on the pharmaceutical market in ASEAN countries, including highlights of the major players &amp; their capabilities, current market data, unique challenges to investors etc?</li> </ul> <ul> <li>Can you list the top 50 drugs in phase II/III development, by annual global revenue potential?(or an approximation thereof)?</li> </ul></td> </tr>  </p>
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 21

AtA typical questions
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 3214

<p> <style type="text/css"> <!-- .links { font-family: Arial, Helvetica, sans-serif; font-size: 12px; text-decoration:none; color:#3399ff; } --> </style><table> <tr> <td> <img height="7" vspace="2" border="0" src="-/media/DDE9E5EC7502434DAE284CE3CC224165.ashx" width="5" hspace="5"><a class="links" href="/asktheanalyst/">Introduction </a></td> <td><img height="7" vspace="2" border="0" src="-/media/DDE9E5EC7502434DAE284CE3CC224165.ashx" width="5" hspace="5"><a href="/asktheanalyst/how_does_it_work/" class="links">How does it work?</a></td> <td><img height="7" vspace="2" border="0" src="-/media/DDE9E5EC7502434DAE284CE3CC224165.ashx" width="5" hspace="5">Typical AtA questions</td> <td><img height="7" vspace="2" border="0" src="-/media/DDE9E5EC7502434DAE284CE3CC224165.ashx" width="5" hspace="5"><a href="/asktheanalyst/bios/" class="links">Biographies </a></td> <td><img height="7" vspace="2" border="0" src="-/media/DDE9E5EC7502434DAE284CE3CC224165.ashx" width="5" hspace="5"><a href="mailto:news.analysis@informa.com?subject=Ask the Analyst - www.clinica.co.uk" class="links">Contact us</a></td> </tr> </table> <table> <tr> <td valign="top" id="small"><escenic_non_breaking_space></escenic_non_breaking_space></td> </tr> <tr> <td valign="top"> <ul type="disc"> <li>Starting from the merger of Pfizer with Wyeth, what are the common therapeutic areas of two companies and particularly which products of Wyeth have close or identical indications to Pfizer&rsquo;s products?</li> </ul> <ul type="disc"> <li><strong>We are trying to look at what might be expected from Government mandated price cuts in Japan in 2010. Any source information that you may have would be much appreciated.<br> </strong><a href="http://www.scripnews.com/home/2010-Scrip-100---Japan-price-cuts-to-sting-at-home-and-abroad-184730">View published response</a><br> </li> </ul> <ul type="disc"> <li><strong>Can you provide me with information about drug availability and reimbursement of medication in the Philippines? <escenic_non_breaking_space></escenic_non_breaking_space> Are brand and generic medicines available and what % of the population has access to healthcare in that country?<br> </strong><a href="http://www.scripnews.com/therapysector/Challenges-and-opportunities-in-the-Philippine-pharma-market-186206">View published response</a><br> </li> </ul> <ul type="disc"> <li>I am looking for an evaluation on the problems and challenges related to the EC Clinical Trials Directive. This means that pharmaceutical companies have to invest strong resources, even if only some molecules arrive to the final step of commercialisation. <escenic_non_breaking_space></escenic_non_breaking_space> I would like to know if there are some referred data on this topic, specifically on the matter of expenditures.</li> </ul> <ul type="disc"> <li>Could you devote a report on the pharmaceutical market in ASEAN countries, including highlights of the major players &amp; their capabilities, current market data, unique challenges to investors etc?</li> </ul> <ul type="disc"> <li>Can you list the top 50 drugs in phase II/III development, by annual global revenue potential?(or an approximation thereof)?</li> </ul></td> </tr> </table> </p> 
----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 38

{2EDCC1FF-26E4-4C6E-AF73-0F43F0F033B8}
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 21

AtA typical questions
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20160622T210913
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

MT038201
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 21

AtA typical questions
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{FF38DC83-07D4-43F0-8C55-84EB64FAF35A}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

227530
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160622T175625Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

c55392d3-6d45-409e-8b20-3a114c3315a3
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160623T010913Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 14

sitecore\admin
----field----
field: {3E431DE1-525E-47A3-B6B0-1CCBEC3A8C98}
name: __Workflow state
key: __workflow state
content-length: 38

{962542F5-554E-4DE8-BE4C-B0796FDAC854}
